Avadel Pharmaceuticals is a biopharmaceutical firm in the US focused on bringing innovative treatments to patients. Its lead product candidate, FT218, is undergoing a Phase 3 clinical trial and targets the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. Founded in 2015, the company is headquartered in Dublin, Ireland and was previously known as Flamel Technologies SA.